Spyre Therapeutics, Inc.
SYRE Nasdaq· Pharmaceutical Preparations
Last close · Oct 23, 2026
$90.33
KIRA · Stoqly’s AI analyst, in plain words
- Spyre Therapeutics, Inc. had $0.0M of revenue in fiscal 2025.
- Spyre Therapeutics, Inc. lost $155M in fiscal 2025.
Market cap
—
P/E
—
Revenue
$0.0M
Net income
−$155M
Free cash flow
—
Operating margin
—
Spyre Therapeutics, Inc. in 30 seconds · fiscal 2025
Does it make a profit?
−$155M
No. It lost money last year.
What Spyre Therapeutics, Inc. does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Feb 19, 2026
- Legal name
- Spyre Therapeutics, Inc.
- CIK
- 0001636282
Spyre Therapeutics, Inc. · SYRE
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | $18.7M | $2.3M | $0.9M | $0.0M | $0.0M |
| Revenue growth | — | −87.6% | −62.0% | −100.0% | — |
| Operating margin | −350.3% | −3,640.2% | −27,348.0% | — | — |
| Net income | −$65.8M | −$83.8M | −$339M | −$208M | −$155M |
| Net margin | −351.1% | −3,598.8% | −38,238.1% | — | — |
| Diluted EPS | −$25.02 | −$24.86 | $13.76 | — | — |
| Cash | |||||
| Cash from operations | −$53.7M | −$80.1M | −$99.9M | −$157M | −$169M |
| Capital expenditure | $0.6M | $0.0M | $0.0M | $0.0M | — |
| Free cash flow | −$54.3M | −$80.2M | −$99.9M | −$157M | — |
| FCF margin | −289.7% | −3,442.8% | −11,276.5% | — | — |
| Share count change | −95.1% | 28.2% | 104.6% | — | — |
| Debt and strength | |||||
| Cash and short-term investments | $93.1M | $55.7M | $339M | $603M | $757M |
| Shareholders' equity | $83.9M | $50.3M | $184M | $518M | $715M |
| Current ratio | 4.9x | 4.2x | 10.7x | 11.3x | 13.3x |
| Returns and quality | |||||
| Return on equity | −58.8% | −124.9% | −289.2% | −59.3% | −25.2% |
| Return on tangible equity | −78.4% | −166.6% | −184.1% | −40.2% | −21.7% |
| Piotroski F-score | 3 | 1 | 3 | — | — |
| Altman Z'' | −6.1 | −20.6 | −3.5 | 4.5 | 11.5 |
Insiders bought, 12 months
$0.0M
0 insiders
Insiders sold, 12 months
$443M
7 insiders
Of sales under plans
9%
$42.0M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Spyre Therapeutics, Inc. · SYRE
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $90.33 a share, the company is worth —.
Source: SEC EDGAR XBRL filings (CIK 0001636282). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.